Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Global muscle relaxant drugs market 3600 synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Region trends
2.1.3 Drug type trends
2.1.4 Dosage form trends
2.1.5 Application trends
2.1.6 Route of administration trends
2.1.7 Distribution channel trends
Chapter 3 Muscle Relaxant Drugs Market Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing geriatric population coupled with chronic diseases
3.2.1.2 Increasing prevalence of musculoskeletal disorders
3.2.1.3 Growing advancement in drug development
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side-effects associated with muscle relaxants
3.2.2.2 Strict regulatory norms
3.3 Growth potential analysis
3.3.1 By drug type
3.3.2 By dosage form
3.3.3 By application
3.3.4 By route of administration
3.3.5 By distribution channel
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022
Chapter 5 Muscle Relaxant Drugs Market Estimates and Forecast, By Drug Type, 2018 - 2032 (USD Million)
5.1 Key trends, by drug type
5.2 Skeletal muscle relaxant drugs
5.3 Neuromuscular blocking agents
5.4 Facial muscle relaxant drugs
Chapter 6 Muscle Relaxant Drugs Market Estimates and Forecast, By Dosage Form, 2018 - 2032 (USD Million)
6.1 Key trends, by dosage form
6.2 Tablet
6.3 Capsule
6.4 Liquid
6.5 Gel, ointments & sprays
Chapter 7 Muscle Relaxant Drugs Market Estimates and Forecast, By Application, 2018 - 2032 (USD Million)
7.1 Key trends, by application
7.2 Muscle spasm & pain relief
7.3 Musculoskeletal disorders
7.4 Surgery
7.5 Other applications
Chapter 8 Muscle Relaxant Drugs Market Estimates and Forecast, By Route of Administration, 2018 - 2032 (USD Million)
8.1 Key trends, by route of administration
8.2 Oral
8.3 Parenteral
8.4 Topical
Chapter 9 Muscle Relaxant Drugs Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 (USD Million)
9.1 Key trends, by distribution channel
9.2 Hospital pharmacy
9.3 Specialty & Retail pharmacy
9.4 Online pharmacy
Chapter 10 Muscle Relaxant Drugs Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)
10.1 Key trends, by region
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East & Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 Rest of Middle East & Africa
Chapter 11 Company Profiles
11.1 Amneal Pharmaceuticals LLC
11.2 Ipsen Biopharmaceuticals, Inc.
11.3 Merz Pharmaceuticals, LLC.
11.4 Mylan (Viatris)
11.5 Sanofi
11.6 Pfizer Inc
11.7 Novartis AG
11.8 Teva Pharmaceuticals Industries Ltd, Inc.
11.9 Vertical Pharmaceuticals
11.10 Sun Pharmaceutical Industries Ltd.
11.11 SteriMax Inc
11.12 Par Pharmaceutical
11.13 Abbott Laboratories
11.14 F. Hoffmann-La Roche AG
